{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-015155","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.388397+00:00","generated_at":"2026-05-15T19:50:06.572547+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TriSalus Q4 revenue $13.2M (+60% YoY); reaffirms 2026 revenue guidance $60-62M","bullets":["Full-year 2025 revenue $45.2M (+53% YoY); Q4 gross margin 86.7% vs 85.3% prior year.","Adjusted EBITDA loss improved to $0.9M in Q4 2025 from $5.7M loss in Q4 2024.","Net loss attributable to common shareholders FY2025 $69.7M ($1.84 loss per share) vs $33.2M ($1.31) prior year.","Raised $46M gross proceeds from public offering post-Q4; cash and equivalents $20.4M at Dec 31, 2025.","Appointed Michael Stansky to board in Feb 2026; launched TriNav XP infusion system."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-015155","json":"https://secwatch.observer/filing/0001628280-26-015155.json","markdown":"https://secwatch.observer/filing/0001628280-26-015155.md","text":"https://secwatch.observer/filing/0001628280-26-015155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026015155/0001628280-26-015155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026015155/tlsi-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:50:06.572547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"62be4f55f4b05d127560c79a5da7f201b86f7a9e","claim":"TriSalus Life Sciences, Inc. reported 2026 results: revenue $60 million to $62 million. Guidance reaffirmed.","evidence_excerpt":"Reaffirms 2026 Revenue Guidance of $60-62 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026015155/0001628280-26-015155-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2026"},{"label":"Revenue","value":"$60 million to $62 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"73799a1b9a282b347cdbfd9ff20630d6d340c0c0","claim":"TriSalus Life Sciences, Inc. reported the year ended December 31, 2025 results: revenue $45.2 million, net income $69.7 million, EPS $1.84.","evidence_excerpt":"Revenue, all from sales of the TriNav system, was $45.2 million for the year ended December 31, 2025, an increase of 53% compared to the same period in 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026015155/0001628280-26-015155-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Revenue","value":"$45.2 million"},{"label":"Net income","value":"$69.7 million"},{"label":"EPS","value":"$1.84"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d31db76134673b0861ff1252fbf50b2db69b6e51","claim":"TriSalus Life Sciences, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $13.2 million.","evidence_excerpt":"Generated $13.2 million in net sales, a 60% increase year-over-year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026015155/0001628280-26-015155-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2025"},{"label":"Revenue","value":"$13.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}